Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...
The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- (“HUTCHMED”) ...
The owners of a “glorified carthorse” who excelled at eventing, brought joy to three generations and was shortlisted for the Horse & Hound Awards have paid tributes to their horse of three lifetimes ...